Adrenal Vein Sampling International Study (AVIS Study)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gian Paolo Rossi, MD, FAHA, FACC, University Hospital Padova
ClinicalTrials.gov Identifier:
NCT01234220
First received: November 2, 2010
Last updated: January 14, 2013
Last verified: January 2013
  Purpose

The AVIS Study is a retrospective multicenter international study that aims to answer a series of questions on the use and performance of adrenal venous catheterization (AVS) for the diagnosis of primary hyperaldosteronism subtype. A questionnaire will be circulated among the centres that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.

The first aim of the AVIS study is to collect summary data on how AVS is being performed throughout the world to answer the following questions:

  • How many AVS studies haw been performed yearly from 2005 to 2010 at each center?
  • How many adrenal vein ruptures occurred during the AVS at each center?Has the rate of adrenal vein rupture been steady or has it changed over the 5 years?
  • How many centers use bilaterally simultaneous and how many use sequential AVS catheterization?
  • How many radiologists perform AVS at each center?
  • How many centers use a cosyntropin stimulation during AVS?
  • What is the percentage of PA patients in whom AVS is performed?
  • How many centres calculate the selectivity index? What is the minimum cutoff used?
  • How many centers calculate the lateralization index? What is the minimum cutoff used?
  • Are the AVS studies that are not bilaterally selective used for diagnosis?
  • How many centers calculate the controlateral suppression index and what is the minimum cutoff used?
  • What is the cost of AVS for the National Health System or Insurance and for patients? The second aim of the study is to calculate the rate of AVS studies that are selective and show lateralization of aldosterone excess at each center by applying predefined set of criteria for defining selectivity and lateralization. Data on the final diagnosis of the PA subtype will be gathered and used as reference to assess the performance of AVS using receiver operating characteristic curves analysis and the Youden index to determine the optimal cutoffs. A worksheet will need to be completed providing information on the following: Demography; Date of AVS;Baseline blood pressure (BP) values and serum K+;Dynamic test during the AVS if any; plasma aldosterone and cortisol concentration in the infra-adrenal inferior vena cava and in the right and left adrenal vein; diagnosis of PA subtype; treatment (adrenalectomy or pharmacological therapy); post-treatment BP and serum K+ values; concordance/discordance between imaging (CT or RM) and AVS.

Condition
Hyperaldosteronism

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Multicenter Study on Use and Interpretation of Adrenal Vein Sampling

Resource links provided by NLM:


Further study details as provided by University Hospital Padova:

Primary Outcome Measures:
  • Number of adrenal vein ruptures occurring during AVS [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • AVS cost for the patient and the health insurance system [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The amount in euros that the patient and the health insurance system has to pay for the AVS study will be estimated in each center.

  • number of selective AVS at right or left side [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The number of selective AVS at right or left side will be calculated using different cutoff values for the selectivity index.

  • number of bilaterally selective AVS [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The number of bilaterally selective AVS will be calculated using different cutoff values for the selectivity index.

  • number of lateralized AVS and number of the patients undergoing adrenalectomy [ Time Frame: January 1st 2005 - November 1st 2010 ] [ Designated as safety issue: No ]
    The number of lateralized AVS will be calculated using different cutoff values for the lateralization index.


Enrollment: 2604
Study Start Date: May 2010
Study Completion Date: November 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Adrenal Venous Sampling (AVS)
Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.

  Hide Detailed Description

Detailed Description:

Background. AVS is recommended by the current Endocrine Society Guideline as the gold standard for the identification of the surgically curable subtype of primary aldosteronism (PA).(Funder 2008) However, consensus on the way AVS should be performed and on the interpretation of its results still lacks, as recently pointed out. (Stewart 2010, Auchus 2010) In particular, some centers use the bilateral simultaneous technique, while others perform the sequential catheterization. Moreover, some centers perform AVS during or after using ACTH stimulation, albeit with different doses, and others do not use any stimulation.(Seccia 2009) In addition, some are utilizing the absolute values of plasma cortisol and aldosterone to determinate the lateralization (Nishikawa 2007), whereas others are relying on calculation of the selectivity index to determine the collection of adrenal vein blood, followed by calculation of the and the lateralization index only if bilaterally selective samples were obtained.(Rossi 2008) Moreover, large differences in the cutoffs for establishing selectivity and lateralization exist, which have not been clarified by recent studies that rather added further complexity to this field.(Mulatero 2010) If a consistent degree of success rate can be achieved by having only one or two radiologists performing AVS at each centre, or if more radiologists can become proficient in performing the procedure and consistently achieving adequate results, also remains to be clarified. Finally, some centers perform AVS in all patients who are plausible candidates to adrenalectomy, while other submit to AVS only a small proportion of the patients (Young WJ personal communication).

Thus, it remains unclear which is the proportion of patients with PA who are offered AVS at the different centers, and how many of those who are submitted to AVS ultimately undergo adrenalectomy.

In an era of shrinking budget the issue of cost the issue of costs of the procedure also remains a relevant one when assessing the cost-effectiveness of the diagnostic work-up of PA. A preliminary survey suggests that there are huge variations across different countries in the charges for AVS to both the patients and/or the health care and insurance system.

It is likely that one of the reasons for the lack of consensus on AVS could depend on the facts that: i) no single centre as gathered a number of AVS studies large enough to warrant solid conclusions; ii) there has been no systematic survey of the AVS data that have been generated around the world in this field

Aims of the study. Based on this background, the aims of the AVIS study are those described above.

Study design. To the first aim a questionnaire will be circulated among the centers that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.

The data will be collected and handled at the maximum level of confidentiality under the requirement of the Declaration of Helsinki.

Study selection criteria. Eligible centers will be identified among those that have published in the English literature on AVS or PA (reported variously as observational cohort studies, or clinical trials): Studies will be identified through computer-assisted literature searches of databases, scanning of reference lists, hand-searching of relevant journals, correspondence with authors of relevant reports and consultation with experts in the field.

The inclusion criteria will be the consent of the leading investigator to participate in the data collection.

The only exclusion criteria will be the refusal to participate in the study. The number of adhering and non-adhering centers will be recorded and mentioned in the publications.

Data collection. Data will be collected in an anonymous way on many characteristics at baseline and at subsequent surveys during follow-up. Information on categorical variables, will be systematically re-coded to ensure comparability among studies. For each individual patient, data were sought on the following outcomes: blood pressure and antihypertensive medications at follow-up post-adrenalectomy and on dates of occurrence of cardiovascular events, including non-fatal CHD; non fatal stroke; specific cause mortality (or at least fatal CDH and fatal stroke) and other cardiovascular outcomes. Being a retrospective study, precise details of the diagnostic criteria used for the definition of incident cases will be sought from each centre (as were data on the completeness of follow-up).

Data obtained from each participating study will be checked for internal consistency and any queries that might arrive will clarified with the P.I. of each centre, before harmonization to a standard format.

The content of the data will be unchanged by this process, and computer-generated detailed summary tabulations based will be reviewed and confirmed by collaborators.

Data will be stored securely and anonymously at the coordinating centre.

Statistical analysis will be performed by use of summary statistics after appropriate transformation of the variables that show a skewed distribution as PAC and PCC by means of the SPSS for Mac (vers 18.0), GaphPad and the MedCalc softwares.

Scientific Committee. The leading investigator of each centre contributing at least 50 AVS studies will be invited to participate in the scientific committee of the AVIS study and will have full access to the locked database.

Expected results. Upon completion of the first phase of the study the investigators expect to be able to gather information on the way AVS is being performed around the world and therefore to prepare a first manuscript reporting on the number of AVS per centre, the rate of adrenal vein ruptures during the procedure, the rate of use of simultaneous/sequential AVS catheterization, the number of radiologists that perform AVS and their success rate in the procedure, the rate of use of stimulation test during the perform of AVS, the percentage of PA patients to whom AVS is offered at each center, the rate of calculation of the selectivity index, the lateralization index and the contralateral suppression index and their cutoff limits, the use of AVS studies that are not bilaterally selective for diagnosis and the costs of AVS for the National Health System or Insurance and for the patients.

Upon completion of the database with the individual data the investigators expect to be able to gather > 2000 AVS studies, in a single database. After harmonization of the data, identification of the outliers and of the underlying reasons (by interaction with the leading investigator at each center), the database will be locked. The investigators will then undertake the statistical analysis, which will entail the following variables:

  • Demography (sex, age, race);
  • Baseline blood pressure (BP) and heart rate (HR) values;
  • Serum K+ before AVS;
  • Dynamic test during the AVS if any;
  • Plasma aldosterone (PAC) and cortisol concentration (PCC) in the infraadrenal inferior vena cava (IVC) and in the right (RAV) and left (LAV) adrenal vein;
  • Final diagnosis (bilateral adrenocortical hyperplasia (BAH), unilateral adrenocortical hyperplasia (UAH), aldosterone-producing adenoma (APA), bilateral APA;
  • Treatment (adrenalectomy or pharmacological therapy);
  • Post-treatment blood pressure (BP) and heart rate (HR) values;
  • Post-treatment sK+ ;
  • Diagnosis concordance/discordance between imaging (CT or RM) and AVS. Data on the demography, biochemical and hemodynamic features of the patients selected for AVS in the different continents will be obtained and information on the rate of successful catheterization will be generated. The concordance rate of imaging and AVS results will also be determined and the clinical usefulness of the AVS for establishing the indication to adrenalectomy will be ascertained in the largest database available ever.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All patients with Primary Aldosteronism who underwent AVS during the last 5 years in 15 worldwide centers.

Criteria

Inclusion Criteria:

  • consent of the leading investigator to participate to the data collection

Exclusion Criteria:

  • refusal of the leading investigator to participate to the AVIS Study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01234220

Locations
United States, Pennsylvania
Hospital of The University of Pennsylvania, Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
United States, Wisconsin
Medical College of Wisconsin
Menomonee Falls, Wisconsin, United States, 53051
Australia
Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes Hospital
Brisbane, Australia, 4120
Canada, Alberta
Foothills Medical Centre, University of Calgary
Calgary, Alberta, Canada
Canada, Quebec
Centre Hospitalier de l'Université de Montreal (CHUM)
Montreal, Quebec, Canada
Czech Republic
General Faculty Hospital, Prague
Prague, Czech Republic
France
University of Paris, Hopital Européen Georges Pompidou
Paris, France
Germany
Christian J Strasburger
Berlin, Germany, 10117
Heinrich Heine Universität Düsseldorf
Düsseldorf, Germany
Medizinische Klinik Innenstadt
Munich, Germany
University Hospital Wuerzburg
Wuerzburg, Germany, 97080
Italy
Dept Clinical and Experimental Medicine (DMCS), University Hospital of Padova, Italy
Padua, Italy
Medicina 2, Dipartimento di Medicina Interna e Specialità Mediche, Azienda Ospedaliera Santa Maria Nuova
Reggio Emilia, Italy, 42123
Japan
National Hospital Organizatio, Kyoto Medical Center
Kyoto, Japan
Tohoku University Hospital
Sendai, Japan
Institute of Clinical Endocrinology, Tokyo Women's Medical University
Tokyo, Japan
Yokohama Rosai Hospital
Yokohama City, Japan
Netherlands
Radboud University Nijmegen Medical Center
Nijmegen, Netherlands, 6525GA
Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Sponsors and Collaborators
University Hospital Padova
Investigators
Study Director: GianPaolo Rossi, MD, FACC Dept Clinical and Experimental Medicine (DMCS), University Hospital of Padova, Italy
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gian Paolo Rossi, MD, FAHA, FACC, MD, FAHA, FACC, University Hospital Padova
ClinicalTrials.gov Identifier: NCT01234220     History of Changes
Other Study ID Numbers: GPR-AVIS
Study First Received: November 2, 2010
Last Updated: January 14, 2013
Health Authority: Italy: Ethics Committee

Keywords provided by University Hospital Padova:
Aldosterone
Primary Aldosteronism
Aldosterone Producing Adenoma (APA)
Idiopathic Adrenal Hyperplasia (IHA)
Adrenal Venous Sampling

Additional relevant MeSH terms:
Hyperaldosteronism
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Epinephrine
Epinephryl borate
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Mydriatics
Adrenergic alpha-Agonists
Sympathomimetics
Vasoconstrictor Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on July 29, 2014